- The FDA has approved Merck & Co Inc MRK immunotherapy Keytruda (pembrolizumab) to treat an early form of breast cancer in combination with chemotherapy.
- The FDA approval is for treating triple-negative breast cancer (TNBC), an aggressive form of the disease with an increased risk of recurrence.
- KEYNOTE-522 Trial data in over 1,000 patients showed that the drug, combined with chemotherapy before surgery and then used as monotherapy after surgery, significantly prolonged event-free survival.
- There was a 37% reduction in the risk of disease progression.
- With this approval, Keytruda is now approved in the U.S. for 30 indications.
- Price Action: MRK shares are up 0.08% at $77.3 during the premarket session on the last check Tuesday.
- Related content: Benzinga's Full FDA Calendar.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
